206 related articles for article (PubMed ID: 37483605)
1. HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy.
Wan X; Young KH; Bai O
Front Immunol; 2023; 14():1216610. PubMed ID: 37483605
[TBL] [Abstract][Full Text] [Related]
2. Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes.
Yan X; Zhou M; Lou Z; Mu Q; Sheng L; Zhang P; Wang Y; Ouyang G
J Cancer Res Ther; 2018; 14(Supplement):S248-S253. PubMed ID: 29578182
[TBL] [Abstract][Full Text] [Related]
3. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma.
Zhou X; Wuchter P; Egerer G; Kriegsmann M; Mataityte A; Koelsche C; Witzens-Harig M; Kriegsmann K
Eur J Haematol; 2019 Oct; 103(4):410-416. PubMed ID: 31338887
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin.
Deng L; Song Y; Young KH; Hu S; Ding N; Song W; Li X; Shi Y; Huang H; Liu W; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Ying Z; Zhang C; Sun Y; Zhu J
Oncotarget; 2015 Sep; 6(28):25061-73. PubMed ID: 26314957
[TBL] [Abstract][Full Text] [Related]
5. Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.
Ni Y; Gao L; Lu Y; Ye S; Zhou L; Qian W; Liang A; Li P
Front Immunol; 2022; 13():982346. PubMed ID: 36119029
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
[TBL] [Abstract][Full Text] [Related]
7. The prognostic roles of hepatitis B virus antibody in diffuse large B-cell lymphoma patients.
Hu S; Chen N; Lu K; Zhen C; Sui X; Fang X; Li Y; Luo Y; Zhou X; Wang X
Leuk Lymphoma; 2021 Jun; 62(6):1335-1343. PubMed ID: 33399486
[TBL] [Abstract][Full Text] [Related]
8. Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study.
Huang HH; Hsiao FY; Chen HM; Wang CY; Ko BS
Br J Haematol; 2021 Jan; 192(1):110-118. PubMed ID: 33131074
[TBL] [Abstract][Full Text] [Related]
9. Splenic large B-cell lymphoma in patients with hepatitis C virus infection.
Takeshita M; Sakai H; Okamura S; Oshiro Y; Higaki K; Nakashima O; Uike N; Yamamoto I; Kinjo M; Matsubara F
Hum Pathol; 2005 Aug; 36(8):878-85. PubMed ID: 16112004
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
[TBL] [Abstract][Full Text] [Related]
11. HBV infection potentiates resistance to S-phase arrest-inducing chemotherapeutics by inhibiting CHK2 pathway in diffuse large B-cell lymphoma.
Zhao X; Guo X; Xing L; Yue W; Yin H; He M; Wang J; Yang J; Chen J
Cell Death Dis; 2018 Jan; 9(2):61. PubMed ID: 29352124
[TBL] [Abstract][Full Text] [Related]
12. Capable Infection of Hepatitis B Virus in Diffuse Large B-cell Lymphoma.
Wang Y; Wang H; Pan S; Hu T; Shen J; Zheng H; Xie S; Xie Y; Lu R; Guo L
J Cancer; 2018; 9(9):1575-1581. PubMed ID: 29760795
[No Abstract] [Full Text] [Related]
13. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
14. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
[TBL] [Abstract][Full Text] [Related]
15. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy.
Chen XQ; Peng JW; Lin GN; Li M; Xia ZJ
Med Oncol; 2012 Jun; 29(2):1237-41. PubMed ID: 21556931
[TBL] [Abstract][Full Text] [Related]
16. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma.
Wang F; Xu RH; Luo HY; Zhang DS; Jiang WQ; Huang HQ; Sun XF; Xia ZJ; Guan ZZ
BMC Cancer; 2008 Apr; 8():115. PubMed ID: 18433487
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment.
Visco C; Finotto S
World J Gastroenterol; 2014 Aug; 20(32):11054-61. PubMed ID: 25170194
[TBL] [Abstract][Full Text] [Related]
18. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
19. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Xu-Monette ZY; Dabaja BS; Wang X; Tu M; Manyam GC; Tzankov A; Xia Y; Zhang L; Sun R; Visco C; Dybkaer K; Yin L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Zhao X; Winter JN; Piris MA; McDonnell TJ; Miranda RN; Li Y; Medeiros LJ; Young KH
Mod Pathol; 2015 Dec; 28(12):1555-73. PubMed ID: 26541272
[TBL] [Abstract][Full Text] [Related]
20. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
